32004-66-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(5-Fluoro-2-methyl-1H-inden-3-yl)acetic acid is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Drug Discovery and Development:
(5-Fluoro-2-methyl-1H-inden-3-yl)acetic acid is recognized for its potential anti-inflammatory and analgesic properties, making it a promising candidate for drug discovery and development. Its ability to modulate biological responses may lead to the creation of novel treatments for pain and inflammation.
Used in Research:
(5-Fluoro-2-methyl-1H-inden-3-yl)acetic acid also serves as a valuable research tool for studying the biological activities of indene-based compounds. It aids scientists in understanding the structure-activity relationships and potential applications of related chemical entities in medicine and biology.
Used in Organic Synthesis Industry:
In the field of organic synthesis, (5-Fluoro-2-methyl-1H-inden-3-yl)acetic acid is employed as a building block for creating a wide range of organic compounds. Its reactivity and structural features make it suitable for various synthetic pathways, contributing to the advancement of chemical research and the development of new materials.

InChI:InChI=1/C12H11FO2/c1-7-4-8-2-3-9(13)5-11(8)10(7)6-12(14)15/h2-3,5H,4,6H2,1H3,(H,14,15)

Upstream product

• 37794-19-7 6-fluoro-2-methylindanone 
• 372-09-8 cyanoacetic acid 
• 105-36-2 ethyl bromoacetate 
• 459-57-4 4-fluorobenzaldehyde 
• 41201-58-5 5-Fluoro-2-Methyl-Indan-1-One 
• 22138-73-4 3-(4-fluorophenyl)-2-methylpropanoic acid 
• 22138-72-3 (E)-3-(4-fluorophenyl)-2-methylacrylic acid 
• 79-11-8 chloroacetic acid 

Downstream Products

• 37794-13-1 methyl 5-fluoro-2-methyl-1H-3-indenylacetate 
• 49627-27-2 5-fluoro-2-methyl-1-(4-methylsulfanylbenzylidene)-3-indenylacetic acid 
• 49627-27-2 sulindac sulfide 
• 61812-45-1 sulindac sulfide 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy

Peroxisome proliferator-activated receptor gamma (PPARγ) is a valuable drug target for diabetic treatment and ligands of PPARγ have shown potent anti-diabetic efficacy. However, to overcome the severe side effects of current PPARγ-targeted drugs, novel PPARγ ligands need to be developed. Sulindac, an identified ligand of PPARγ, is widely used in clinic as a non-steroidal anti-inflammatory drug. To explore its potential application for diabetes, we designed and synthesized a series of sulindac derivatives to investigate their structure-activity relationship as PPARγ ligand and potential anti-diabetic effect. We found that meta-substitution in sulindac's benzylidene moiety was beneficial to PPARγ binding and transactivation. Z rather than E configuration of the benzylidene double bond endowed derivatives with the selectivity of PPARγ activation. The indene fluorine is essential for binding and regulating PPARγ. Compared with rosiglitazone, compound 6b with benzyloxyl meta-substitution and Z benzylidene double bond weakly induced adipogenesis and PPARγ-targeted gene expression. However, 6b potently improved glucose tolerance in a diabetic mice model. Unlike rosiglitazone, 6b was devoid of apparent toxicity to osteoblastic formation. Thus, we provided some useful guidelines for PPARγ-based optimization of sulindac and an anti-diabetic lead compound with less side effects.

O-carborane derivative, synthesis method and application thereof

The invention discloses an o-carborane derivative and a synthesis method thereof. The method includes: step 1, taking 5-fluoro-2-methyl-1H-indene or 5-trifluoromethyl-2-methyl-1H-indene as a reactioninitiator, adopting aluminum trichloride as a catalyst, and carrying out reaction with 1-chloroacetic acid to obtain an intermediate 2; step 2, reacting the intermediate 2 with N-bromosuccinimide by taking DMF as a reaction solvent to obtain an intermediate 3; and step 3, reacting the intermediate 3 with o-carborane in an organic solvent or ionic liquid under an alkaline condition to obtain the corresponding o-carborane derivative. According to the invention, fluorine ions and relative hydrophilic groups are introduced for modification through chemical synthesis, the purposes of reducing toxicity and increasing compound polarity and cell affinity are achieved, so that the technical effect of targeted enrichment and high concentration of boron ions in tumor cells is achieved, and then the technical bottleneck that p-borane phenylalanine (BPA) is discharged by an anti-transport mechanism after the concentration of the BPA in the tumor cells reaches a certain number 1 is solved.

Design, synthesis and biological evaluation of tetrazole-containing RXRα ligands as anticancer agents

Nuclear receptor RXRα plays an important role in many biological and pathological processes. The nongenomic action of RXRα is implicated in many cancers. K-8008, a non-canonical RXRα ligand derived from sulindac, inhibits the TNFα-activated PI3K/AKT pathway by mediating the interaction between a truncated form of RXRα (tRXRα) and the p85α regulatory subunit of PI3K and exerts potent anticancer activity in animal model. Herein we report our studies of a novel series of K-8008 analogs as potential anticancer agents targeting RXRα. Two compounds 8b and 18a were identified to have slightly stronger binding to RXRα and improved apoptotic activities in breast cancer cells.

COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER

Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in treating or preventing diseases, for example, cancer.

INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES

Disclosed are compounds, for example, a compound of formula I, wherein R, R0, R1-R8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Method for treating a patient with neoplasia using Iressa

This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.

Methods for treatment of rheumatoid arthritis

Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of rheumatoid arthritis.

Methods for treatment of diseases where GSK 3-beta is desired, and methods to identify compounds usefule for that

A method for selecting compounds for the treatment of diseases where GSK3β is desired includes assessing whether the compounds cause an increase in PKG activity in the tissue of interest.

Methods for treatment of multiple sclerosis

Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of multiple sclerosis.